Summit Therapeutics receiving Fast Track designation from the FDA for its lead utrophin modulator, ezutromid, in the treatment of DMD is a positive step for the group and highlights ezutromid’s potential of addressing a life threatening disorder. A Phase II proof-of-concept trial (PhaseOut DMD) is ongoing with the first muscle biopsy data expected Q2/Q3 2017. A placebo controlled trial is expected to start in H2 2017, assuming positive interim data from the PhaseOut DMD trial.
